Literature DB >> 19075654

Antioxidants and neuroprotection in the adult and developing central nervous system.

Charanjit Kaur1, Eng-Ang Ling.   

Abstract

Oxidative stress is implicated in the pathogenesis of a number of neurological disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis and stroke in the adult as well as in conditions such as periventricular white matter damage in the neonatal brain. It has also been linked to the disruption of blood brain barrier (BBB) in hypoxic-ischemic injury. Both experimental and clinical results have shown that antioxidants such as melatonin, a neurohormone synthesized and secreted by the pineal gland and edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a newly developed drug, are effective in reducing oxidative stress and are promising neuroprotectants in reducing brain damage. Indeed, the neuroprotective effects of melatonin in many central nervous system (CNS) disease conditions such as amyotrophic lateral sclerosis, PD, AD, ischemic injury, neuropsychiatric disorders and head injury are well documented. Melatonin affords protection to the BBB in hypoxic conditions by suppressing the production of vascular endothelial growth factor and nitric oxide which are known to increase vascular permeability. The protective effects of melatonin against hypoxic damage have also been demonstrated in newborn animals whereby it attenuated damage in different areas of the brain. Furthermore, exogenous administration of melatonin in newborn animals effectively enhanced the surface receptors and antigens on the macrophages/microglia in the CNS indicating its immunoregulatory actions. Edaravone has been shown to reduce oxidative stress, edema, infarct volume, inflammation and apoptosis following ischemic injury of the brain in the adult as well as decrease free radical production in the neonatal brain following hypoxic-ischemic insult. It can counteract toxicity from activated microglia. This review summarizes the clinical and experimental data highlighting the therapeutic potential of melatonin and edaravone in neuroprotection in various disorders of the CNS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075654     DOI: 10.2174/092986708786848640

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  25 in total

1.  Proteomic and metabolomic profiling of a trait anxiety mouse model implicate affected pathways.

Authors:  Yaoyang Zhang; Michaela D Filiou; Stefan Reckow; Philipp Gormanns; Giuseppina Maccarrone; Melanie S Kessler; Elisabeth Frank; Boris Hambsch; Florian Holsboer; Rainer Landgraf; Christoph W Turck
Journal:  Mol Cell Proteomics       Date:  2011-08-23       Impact factor: 5.911

2.  Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon β-1b.

Authors:  Lijian Yu; Ed Croze; Ken D Yamaguchi; Tiffany Tran; Anthony T Reder; Vladimir Litvak; Michael R Volkert
Journal:  J Interferon Cytokine Res       Date:  2014-10-20       Impact factor: 2.607

3.  Mn (III) tetrakis (4-benzoic acid) porphyrin protects against neuronal and glial oxidative stress and death after spinal cord injury.

Authors:  Lokanatha Valluru; Yao Diao; Jorge E Hachmeister; Danxia Liu
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-09       Impact factor: 4.388

Review 4.  Environmental control of autoimmune inflammation in the central nervous system.

Authors:  Veit Rothhammer; Francisco J Quintana
Journal:  Curr Opin Immunol       Date:  2016-10-04       Impact factor: 7.486

5.  Effects of edaravone on amyloid-β precursor protein processing in SY5Y-APP695 cells.

Authors:  Yue-E Shen; Yan Wang; Gui-Chun Yu; Chao Liu; Zhen-Yu Zhang; Li-Ming Zhang
Journal:  Neurotox Res       Date:  2013-01-17       Impact factor: 3.911

6.  N-acetyl-L-cysteine protects against cadmium-induced neuronal apoptosis by inhibiting ROS-dependent activation of Akt/mTOR pathway in mouse brain.

Authors:  Sujuan Chen; Qian Ren; Jinfei Zhang; Yangjing Ye; Zhen Zhang; Yijiao Xu; Min Guo; Haiyan Ji; Chong Xu; Chenjian Gu; Wei Gao; Shile Huang; Long Chen
Journal:  Neuropathol Appl Neurobiol       Date:  2014-10       Impact factor: 8.090

7.  CK2 is a novel negative regulator of NADPH oxidase and a neuroprotectant in mice after cerebral ischemia.

Authors:  Gab Seok Kim; Joo Eun Jung; Kuniyasu Niizuma; Pak H Chan
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

8.  Nitric oxide as an initiator of brain lesions during the development of Alzheimer disease.

Authors:  Gjumrakch Aliev; Hector H Palacios; Amanda E Lipsitt; Kathryn Fischbach; Bruce T Lamb; Mark E Obrenovich; Ludis Morales; Eldar Gasimov; Valentin Bragin
Journal:  Neurotox Res       Date:  2009-05-30       Impact factor: 3.911

9.  The role of melatonin in anaesthesia and critical care.

Authors:  Madhuri S Kurdi; Tushar Patel
Journal:  Indian J Anaesth       Date:  2013-03

10.  Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration.

Authors:  Kevin Gregory-Evans; Francis Chang; Matthew D Hodges; Cheryl Y Gregory-Evans
Journal:  Mol Vis       Date:  2009-05-13       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.